Different Doses Rosuvastatin Effect on Telomere-telomerase System in Acute Coronary Syndrome Patients After Percutaneous Coronary INtervention: RETAIN Study
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 05 Jul 2017
At a glance
- Drugs Rosuvastatin (Primary)
- Indications Acute coronary syndromes
- Focus Biomarker; Pharmacodynamics
- Acronyms RETAIN
- 13 Jul 2015 Planned End Date changed from 1 Nov 2015 to 1 Nov 2016 as reported by ClinicalTrials.gov record.
- 13 Jul 2015 Planned primary completion date changed from 1 Jun 2015 to 1 Jul 2016 as reported by ClinicalTrials.gov record.
- 28 Nov 2014 New trial record